Article Details
Retrieved on: 2025-01-29 16:27:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses how the SGLT2 inhibitor empagliflozin reduces the risk of calcium and uric acid kidney stones in non-diabetic patients, linking to natural medicine by involving kidney diseases and solute carriers in treatment.
Article found on: www.renalandurologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here